A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 339 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Gilteritinib Improves Survival in AML with FLT3 Mutations November 27, 2019 Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast... October 25, 2022 FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers... November 10, 2020 Girl Scout’s Pink Chair Project Loans Recliners to Women Recovering from... December 21, 2021 Load more HOT NEWS Could proton beam therapy improve throat cancer treatment? Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality... The First Report from the Cancer Programme of the 100,000 Genomes... Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation...
